Category Archives: Prevention, Engagement and Care Cascade

Characterizing the role of intersecting stigmas and sustained inequities in driving HIV syndemics across low-to-middle-income settings

2020

PURPOSE OF REVIEW: In 2020, key populations around the world still have disproportionate risks for HIV acquisition and experiencing HIV-related syndemics. This review presents current data around HIV-related syndemics among...

Shared immunotherapeutic approaches in HIV and hepatitis B virus: Combine and conquer

2020

PURPOSE OF REVIEW: The aim of this study was to identify similarities, differences and lessons to be shared from recent progress in HIV and hepatitis B virus (HBV) immunotherapeutic approaches....

Challenges and opportunities for hepatitis B cure in the setting of HIV–Hepatitis B virus co-infection

2020

PURPOSE OF REVIEW: To examine issues specific to HIV–HBV co-infection that are relevant to the search for and achieving hepatitis B cure in this the setting RECENT FINDINGS: In HIV–HBV...

Enhancing care for people living with HIV: Current and future monitoring approaches

2021

INTRODUCTION: Antiretroviral therapy (ART) is the most significant advance in the medical management of HIV-1 infection. Given the fact that HIV cannot be eradicated from the body, ART has to...

Adolescents and young adults with early acquired HIV infection in the United States: Unique challenges in treatment and secondary prevention

2021

INTRODUCTION: Worldwide, children who acquired human immunodeficiency virus (HIV) at an early age, either perinatally or through blood transfusion, are reaching adolescence and adulthood due to successful antiretroviral treatment (ART)....

Efavirenz versus protease inhibitors in patients with HIV: A systematic review and meta-analysis

2021

Efavirenz- and protease inhibitor (PI)-based regimens remain viable options across the globe. We conducted a meta-analysis to compare the effectiveness of efavirenz-based regimens relative to PI-based regimens. EMBASE, PubMed, Cochrane,...

Low inducibility of latent human immunodeficiency virus type 1 proviruses as a major barrier to cure

2021

The latent reservoir for human immunodeficiency virus type 1 (HIV-1) in resting CD4+ T cells is a major barrier to cure. The dimensions of the reservoir problem can be defined...

Evidence and gaps in the literature on HIV/STI prevention interventions targeting migrants in receiving countries: A scoping review

2021

BACKGROUND: Evidence suggests that migration increases vulnerability to human immunodeficiency virus (HIV) and other sexually transmitted infections (STI). However, there is limited knowledge about what has been done or needs...

Recommendations for increasing physician provision of pre-exposure prophylaxis: Implications for medical student training

2021

There is growing evidence that pre-exposure prophylaxis (PrEP) prevents HIV acquisition. However, in the United States, approximately only 4% of people who could benefit from PrEP are currently receiving it,...

1,2,3-Triazole hybrids with anti-HIV-1 activity

2021

The human immunodeficiency virus type 1 (HIV-1) is the major etiological agent responsible for the acquired immunodeficiency syndrome (AIDS), which is a serious infectious disease and remains one of the...

Differences in outcomes of chemoradiation in women with invasive cervical cancer by human immunodeficiency virus status: A systematic review

2021

PURPOSE: Cervical cancer is one of the leading causes of cancer death among women worldwide, and women living with human immunodeficiency virus (HIV) carry the highest burden of disease. Chemoradiation...

A review of potential microbiome-gut-brain axis mediated neurocognitive conditions in persons living with HIV

2020

The microbiome-gut-brain axis, or the various interactions between the gut microbiome and the brain, has been of recent interest in the context of precision medicine research for a variety of...

Email 1 selected articles

Email 1 selected articles

Error! The email wasn't sent. Please try again.

Your email has been sent!